Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 85

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 85
---
 |          |           |    |
|                            |     |           | 3/1/2024 |     |            | PSUs             |     |                            |   |     |           |         |     |        |         |     |                          | — |     | 17,000 | -5 |     | 17,000 | -5 |     |           |        |    |     |            |         |     |          |       |     |          |         — | -5 |
|                            |     |           | 3/1/2024 |     |            | RSUs             |     |                            |   |     |           |         |     |        |         |     |                          | — |     |        |    |     |        |    |     |           | 17,000 | -6 |     |            |         |     |          |       |     |          |   548,590 |    |
|                            |     |           | 3/1/2024 |     |            | Stock Options    |     |                            |   |     |           |         |     |        |         |     |                          | — |     |        |    |     |        |    |     |           |        |    |     |            |  60,000 |     |          | 32.27 |     |          | 1,068,185 |    |

| (1) | Amounts shown in the threshold, target and maximum columns reflect the minimum, target and maximum amounts, respectively, payable under our annual incentive cash program as described above under “Annual Performance-based Cash Incentives”. Actual amounts paid for 2024 performance are presented in the “Non-equity Incentive Plan Compensation” column of the Summary Compensation Table above. |

64

| (2) | Options subject to time-based vesting criteria established by the compensation & people committee or board of directors, as applicable, and described in the footnotes to the Outstanding Equity Awards at Fiscal Year End table below. |

| (3) | The exercise price per share of these stock options is equal to the closing price of our common stock on the grant date. |

| (4) | Amounts listed represent the aggregate fair value amount computed as of the grant date of the awards granted in accordance with FASB ASC Topic 718. Assumptions used in the calculation of these amounts are included in Note 9, Share-Based Payments, of